Prognostic Factors and a Nomogram Predicting Survival in Patients with Breast Ductal Carcinoma in situ with Microinvasion: A Population-Based Study

• Published in: Clinical epidemiology Vol. 13; pp. 1095 - 1108
• Main Authors: Zheng, Yi-Zi, Qin, Hong-Bin, Li, Zi-Zheng, Jiang, He-Sheng, Zhang, Greg, Yang, Shi-Wei, Wang, Xian-Ming, Xu, Yang-Chun, Deng, Zhen-Han, Liu, Guo-Wen
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2021; Taylor & Francis Ltd; Dove; Dove Medical Press
• Subjects: Age; Breast cancer; Calibration; Cancer; Cancer therapies; Carcinoma, Ductal; Chemotherapy; Clinical medicine; Disease; ductal carcinoma in situ; Epidemiology; Estrogen; Estrogens; Mammography; Medical prognosis; microinvasion; nomogram; Nomograms; Oncology, Experimental; Original Research; Patient outcomes; Patients; Population; Population-based studies; Progesterone; Prognosis; Radiation; Software; Surgery; Surveillance; survival; Variables; White people; China; ductal carcinoma in situ; microinvasion; breast cancer; nomogram; survival
• ISSN: 1179-1349; 1179-1349
• DOI: 10.2147/CLEP.S341422

Ductal carcinoma in situ with microinvasion (DCISM) can be challenging to balance the risks of overtreatment versus undertreatment. We aim to identify prognostic factors in patients with DCISM and construct a nomogram to predict breast cancer-specific survival (BCSS). A retrospective cohort study of women diagnosed with DCISM from 1988 to 2015 who were identified in the Surveillance, Epidemiology and End Results database. Clinical variables and tumor characteristics were evaluated, and Cox proportional-hazards regression was performed. A nomogram was constructed from the multivariate logistic regression to combine all the prognostic factors to predict the prognosis of DCISM patients at 5 years, 10 years, and 15 years. We identified 5438 total eligible breast cancer patients with a median and max survival time of 78 and 227 months, respectively. Here, patients with poorer survival outcomes were those diagnosed between 1988 and 2001, African-American race, under 40 years of age, higher tumor N stage, progesterone receptor-negative tumor, and received no surgery. The nomogram was constructed by the seven variables and passed the calibration and validation steps. The area under the receiver operating characteristic (ROC) curve (AUC) of both the training set and the validating set (5-year AUC: 0.77 and 0.88, 10-year AUC: 0.75 and 0.73, 15-year AUC: 0.72 and 0.65). Receiving chemotherapy was associated with a better BCSS (hazard ratio, HR=0.45, 95% confidence interval, 95% CI = 0.23-0.89), especially in patients with estrogen receptor (ER) negative, progesterone receptor (PR) negative (HR = 0.35, 95% CI = 0.13-0.97) and ER+PR-/ER-PR+ DCISM (HR = 0.07, 95% CI = 0.01-0.59). Our current study is the first to construct nomograms of patients with DCISM which could help physicians identify breast cancer patients that more likely to benefit from more intensive treatment and follow-up. Chemotherapy might benefit patients with ER-PR- and ER+PR-/ER-PR+ DCISM.